2-tert-butyl-2-oxo-5,5-dimethyl-1,3,2-dioxaphosphorinane | 15761-94-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: 2-tert-butyl-2-oxo-5,5-dimethyl-1,3,2-dioxaphosphorinane
• 英文别名: 2-Oxo-2-tert.-butyl-5,5-dimethyl-1,3,2-dioxaphosphorinan；2-Tert-butyl-5,5-dimethyl-1,3,2lambda5-dioxaphosphinane 2-oxide；2-tert-butyl-5,5-dimethyl-1,3,2λ5-dioxaphosphinane 2-oxide
• CAS: 15761-94-1
• 化学式: C₉H₁₉O₃P
• 分子量: 206.222
• InChiKey: SUFDIIAWUASKBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2,2-二甲基-1,3-丙二醇 、 叔丁基二氯化膦 在 三乙胺 作用下， 以 1,4-二氧六环 、 乙醚 为溶剂， 反应 17.5h， 以61%的产率得到2-tert-butyl-2-oxo-5,5-dimethyl-1,3,2-dioxaphosphorinane
  参考文献：
  名称：

  Synthesis and stereochemistry of 4-tert-butyl-4-oxo-3,5,8-trioxa (3,5-dioxa-8-thia)-4-phosphabicyclo [5.1.0]octanes and related acetals

  摘要：

  X-ray, H-1 NMR and IR spectroscopy methods have been applied to a series of heterobicyclo[5.1.0]octanes. Endo epoxide and exo thiirane based on 2-tert-butyl-2-oxo-1,3,2-dioxaphosphepine exhibit chair form in a crystal state. Strong predominance of the chair conformation takes place in solution also as for similar bicyclic acetals produced from 2-tert-butyl-1,3-dioxacyclohept-5-ene. 3,5-Dioxa-8-thiabicyclo[5.1.0] octane bearing no a bulky substituent was found to exist as a mixture of stereoisomers in solution. (c) 2006 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.molstruc.2006.09.033

文献信息

• Heterocyclic Compounds
  申请人：Yen Chi-Feng

  公开号：US20090264339A1

  公开（公告）日：2009-10-22

  This invention relates to heterocyclic compounds of the formulas shown in the specification. It also relates to methods for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, and tissue injuries with one of the heterocyclic compounds.

  这项发明涉及规范中所示的异环化合物。它还涉及使用其中一种异环化合物治疗炎症性疾病或免疫性疾病、发育性或退行性疾病以及组织损伤的方法。
• Cyclic organophosphorus compounds—V
  作者：K.D. Bartle、R.S. Edmundson、D.W. Jones

  DOI：10.1016/s0040-4020(01)82569-2

  日期：1967.1

  and 4 chemical bonds, are reported for the 5,5-substituted-1,3-2-dioxaphosphorinanes (I: X = O or S; R1 = R2 = Me or Et; R1 = Me, R2 = ClCH2; R3 = alkyl, alkoxy, aryloxy, alkylamido, halogeno, H,). In some cases, the 4,6-methylene hydrogen resonances have been analysed by means of an ABX approximation.

  质子化学位移，和31个P- 1个通过的1,2,3序列ħ偶合常数，和4个化学键，报道了5,5-取代的1,3-2-dioxaphosphorinanes（I：X = O或S； R 1＝ R 2＝ Me或Et； R 1＝ Me，R 2＝ ClCH 2； R 3＝烷基，烷氧基，芳氧基，烷基酰胺基，卤代，H 1。在某些情况下，已经通过ABX近似分析了4,6-亚甲基氢共振。
• Non-Halogen Flameproof Resin Composition
  申请人：LEE Min Soo

  公开号：US20100216921A1

  公开（公告）日：2010-08-26

  A non-halogen flameproof resin composition is disclosed. The resin composition includes a base resin including (A) about 80 to about 99% by weight of an aromatic vinyl resin and (B) about 1 to about 20% by weight of a polyphenylene ether; and (C) about 0.5 to about 30 parts by weight of a cyclic t-butyl phosphonate, based on about 100 parts by weight of the base resin comprising (A) and (B).

  本发明涉及一种非卤素阻燃树脂组合物。该树脂组合物包括基础树脂，包括（A）约80至约99重量％的芳香族乙烯树脂和（B）约1至约20重量％的聚苯醚；以及（C）约0.5至约30重量份的环状叔丁基膦酸酯，基于包括（A）和（B）的基础树脂约100重量份。
• LYOPHILIZATION FORMULATION
  申请人：Yen Chi-Feng

  公开号：US20100120719A1

  公开（公告）日：2010-05-13

  This invention relates to a pharmaceutical kit containing a lyophilized preparation of a pyrimidine compound described in the specification. Also disclosed is a lyophilization process for making this preparation.

  这项发明涉及一种药物工具包，其中包含本说明书中描述的嘧啶化合物的冻干制剂。还公开了制备该制剂的冻干化过程。
• ALVOCIDIB PRODRUGS AND THEIR USE AS PROTEIN KINASE INHIBITORS
  申请人：SAWAYAMA Yusuke

  公开号：US20200048228A1

  公开（公告）日：2020-02-13

  Compounds having the following structure (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 and R 3 are as defined herein, and wherein at least one of R 1 , R 2 and R 3 is not H, are provided. Pharmaceutical compositions comprising the compounds and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.